SOPHiA GENETICS (NASDAQ:SOPH) Posts Earnings Results, Hits Estimates

SOPHiA GENETICS (NASDAQ:SOPH) issued its quarterly earnings results on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.23), Zacks reports. SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. SOPHiA GENETICS updated its FY 2025 guidance to EPS.

SOPHiA GENETICS Stock Down 2.7 %

SOPH opened at $3.57 on Tuesday. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.80 and a quick ratio of 3.59. SOPHiA GENETICS has a 12 month low of $2.70 and a 12 month high of $7.37. The stock has a market capitalization of $233.39 million, a P/E ratio of -3.28 and a beta of 1.03. The business has a 50 day simple moving average of $3.58 and a 200-day simple moving average of $3.56.

Wall Street Analyst Weigh In

Separately, Craig Hallum started coverage on SOPHiA GENETICS in a research note on Wednesday, December 18th. They set a “buy” rating and a $11.00 price target for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $7.40.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.